Heart disease test maker Singulex files for $86M IPO

Alameda diagnostic test developer Singulex Inc. filed for an $86.25 million initial public offering Friday, promising a test to measure signs of heart disease at previously undetectable levels. Using the Jumpstart Our Business Startups, or JOBS, Act to qualify as an "emerging growth company," 15-year-old Singulex said in a filing with the Securities and Exchange Commission that its technology helps to earlier detect and monitor biomarkers of heart attacks, heart failure, stroke and other heart diseases.